Patent intelligence · US
US 2024390367
METHODS OF TREATING VITILIGO WITH UPADACITINIB
METHODS OF TREATING VITILIGO WITH UPADACITINIB
Patent details — US 2024390367
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2024
- Expiration
- Nov 23, 2044
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 31/ 4985 A I, A61K 47/ 12 A I
Quick answer
US 2024390367 (METHODS OF TREATING VITILIGO WITH UPADACITINIB) is held by ABBVIE INC [US]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 31/ 4985 A I, A61K 47/ 12 A I, A61K/314985, A61K/4712
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2024390367?
US 2024390367 (METHODS OF TREATING VITILIGO WITH UPADACITINIB) is held by ABBVIE INC [US]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2024390367?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 2024390367 expire?
Our index shows an expiration date of Nov 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.